DAI, Suite 440, Southbank House, Black Prince Road, London NW51JH, UK.
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2743-7. doi: 10.1098/rstb.2011.0040.
The Global Alliance for Vaccines and Immunization (GAVI), now 10 years old, was established as a successful and innovative public-private partnership to deal with a fundamental inequity. The poorest children in the poorest parts of the world were being denied access to life-saving vaccines simply on the basis of cost. GAVI has been successful in mobilizing significant funding from donors and through innovative financing instruments, immunizing large numbers of children. GAVI has been less successful, at least in the time frames first envisaged, at quickly reducing the prices of new and under-used vaccines to levels affordable by the poorest countries. Vaccines remain some of the most cost effective of public health interventions. As GAVI seeks to introduce a new set of vaccines to tackle major killers such as pneumonia and diarrhoea, and emerging threats such as cervical cancer, it needs to raise significant additional funds. There is no single solution. Multiple and new instruments will be required to raise finance both globally and at the country level, and also to incentivize industry and others to provide vaccines at affordable prices to the poorest countries.
全球疫苗免疫联盟(GAVI)成立至今已有 10 年,是一个成功且富有创新精神的公私合作伙伴关系,旨在解决一个根本性的不平等问题。世界上最贫穷地区的最贫困儿童由于费用问题而无法获得救命疫苗。GAVI 通过动员来自捐助方的大量资金和创新性融资工具,成功地为大量儿童进行了免疫接种。但至少在最初设想的时间框架内,GAVI 并没有成功地迅速降低新疫苗和使用较少的疫苗的价格,使其达到最贫穷国家能够负担得起的水平。疫苗仍然是公共卫生干预措施中最具成本效益的手段之一。随着 GAVI 寻求引入一系列新疫苗来应对肺炎和腹泻等主要杀手以及宫颈癌等新出现的威胁,它需要筹集大量额外资金。没有单一的解决方案。需要多种新的手段在全球和国家层面筹集资金,还需要激励企业和其他方面以可负担的价格向最贫穷国家提供疫苗。